See this page online at: http://www.bioscienceworld.ca/CytochromaInccompletes21millioninfinancingforvitaminDtechnologies
Sign up for your subscription and keep up-to-date.
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
Cytochroma Inc., a spin-off of Queen's University's PARTEQ Innovations, has secured Cdn$21 million in new financing to advance its product development programs targeting vitamin D deficiency and related diseases in chronic kidney disease.
The new funding will support clinical trials with three investigational new drug products, which began earlier this year.
The VenGrowth Advanced Life Sciences Fund, Nova A/S and GeneChem Technologies Venture Fund led the financing round.
Cytochroma was founded in 1996 by PARTEQ Innovations and Queen's scientists Martin Petkovich and Glenville Jones to develop and identify drug candidates aimed at modulating effects of cytochrome P450's, the key enzyme involved in the metabolism of major biological signalling molecules.
Last year the company acquired Proventiv Therapeutics LLC of Madison, WI, expanding Cytochroma’s broad vitamin D product portfolio and positioning the company to exploit current and future opportunities in chronic kidney disease (CKD), psoriasis, cancer, vitamin D deficiency and related disorders.
